1. The SOLVD Investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fraction and congestive heart failure. N Engl J Med 1991; 325: 293-302.
2. MERIT4HF study group. Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT4HF). Lancet 1999; 353: 293-302.
3. Pitt B, Zannad F, Remme WJ, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomised Aldactone Evaluation Study Investigators. N Engl J Med 1999; 341: 709-17.
4. Агеев Ф.Т., Даниелян М.О., Мареев Ю.В., Беленков Ю.Н. Больные с хронической сердечной недостаточностью в российской амбулаторной практике: особенности контингента, диагностики и лечения (по материалам исследования ЭПОХА4О4ХСН). Серд недостат 2004; 1: 4-7.
5. Vasan RS, Benjamin EL, Levy D. Congestive heart failure with normal left ventricular systolic function: clinical approaches to the diagnosis and treatment of diastolic heart failure. Arch Intern Med 1996; 156(2): 146-65.
6. Slama M, Susic D, Varagic J, et al. Diastolic dysfunction in hypertension. Curr Opin Cardiol 2002; 17: 368-73.
7. Lerman A, Gibbons RJ, Rodeheffer RJ. Circulating N-terminal atrial natriuretic peptide as a marker for symptomless left-ventricular dysfunction. Lancet 1993; 341: 1105-9.
8. Davis M, Espiner E, Richards G, et al. Plasma brain natriuretic peptide in assessment of acute dyspnea. Lancet 1994; 343: 440-4.
9. Levin RE, Gardner DG, Samson WK. Natriuretic peptides. N Engl J Med 1998; 339: 321-8.
10. Melo LG, Pang SC, Ackermann U. Atrial natriuretic peptide: regulator of chronic arterial blood pressure. News Physiol Sci 2000; 15: 143-9.
11. De Bold AJ, Bruneau BG, De Bold K. Mechanical and neuroendocrine regulation of the endocrine heart. Cardiovasc Res 1996; 31: 7-18.
12. Kinnunen P, Vuolteenaho O, Ruskoah H. Mechanisms of atrial and brain natriuretic peptide release from rat ventricular myocardium: effect of stretching. Endocrinology 1993; 132: 1961-70.
13. Richards AM, Crozier JG, Yandle TG, et al. Brain natriuretic factor: regional plasma concentrations and correlations with haemodynamic state in cardiac disease. Br Heart J 1993; 69: 414-7.
14. Haug C, Metzele A, Kochs M, et al. Plasma brain natriuretic peptide and atrial natriuretic peptide concentrations correlate with left ventricular end4diastolic pressure. Clin Cardiol 1993; 15: 553-7.
15. JC, Glants SA. Determinants of left ventricular filling and of the diastolic pressure-volume relaxation. Circ Res 1989; 64: 827-52.
16. Maeda K, Tsutamoto T, Wada A, et al. Plasma brain natriuretic peptide as a biochemical marker of high left ventricular end-diastolic pressure in patients with symptomatic left ventricular dys4 function. Am Heart J 1998; 135: 825-32.
17. Iwanaga Y, Nishi I, Furuichi S, et al. B-Type Natriuretic Peptide Strongly Reflects Diastolic Wall Stress in Patients With Chronic Heart Failure. Comparison Between Systolic and Diastolic Heart Failure. JACC 2006; 47: 742-8.
18. Hannah A, Clements S, McDonagh TA, et al. Low prevalence of isolated diastolic dysfunction in a cohort of suspected heart failure patients ant its relationship to brain natriuretic peptide. Eur Heart J 2003; 24 Abstract (Suppl.): 400.
19. Lubien E., DeMaria A, Krishnaswamy P, et al. Utility of B-natriuretic peptide in detecting diastolic dysfunction. Comparison with Doppler velocity recordings. Circulation 2002; 105: 595-601.
20. Thambidorai SK, Troughton RW, Parakh K, et al. Utility of B-type natriuretic peptide in primary diastolic dysfunction: a quantitative comparison with Doppler echocardiographic indices. JACC 2003; 24 Abstract (Suppl.): 400.
21. Bettencourt P, Ferreira A, Dias P, et al. Evaluation of brain natriuretic peptide in the diagnosis of heart failure. Cardiology 2000; 93: 19-21.
22. Yamamoto K, Burnett JCJr, Jougasaki M, et al. Superiority of brain natriuretic peptide as a hormonal marker of ventricular systolic and diastolic dysfunction and ventricular hypertrophy. Hypertension 1996; 28: 988-94.
23. Yamaguchi H, Yoshida K, Sakata Y. Elevation of plasma brain natriuretic peptide is a hallmark of diastolic heart failure independent of ventricular hypertrophy. Am J Cardiol 2004; 43: 55-60.
24. Schillaci G, Verdecchia P, Porcellati C, et al. Continuous relation between left ventricular mass and cardiovascular risk in essential hypertension. Hypertension 2000; 35: 580-6.
25. Devereux RB, Roman MJ, Liu JE, et al. Congestive heart failure despite normal left ventricular systolic function in a population-based sample: the strong heart study. Am J Cardiology 2000; 86: 1090-6.
26. O`Connor CM, Gattis WA, Shaw L, et al. Clinical characteristics and long-term outcome of patients with heart failure and preserved systolic function. Am J Cardiol 2000; 86: 863-7.
27. Kohno M, Horio T, Yokokawa K, et al. Brain natriuretic peptide as a cardiac hormone in essential hypertension. Am J Med 1992; 92: 29-34.
28. Luchner A, Burnett JCJr, Jougasaki M, et al. Evaluation of brain natriuretic peptide as a marker of left ventricular dysfunction and hypertrophy in the population. J Hypertens 2000; 18: 1121-8.
29. Suzuki M, Yamamoto K, Watanabe S, et al. Associates between elevated brain natriuretic peptide levels and the development of left ventricular hypertrophy in patients with essential hyperten4 sion. Am J Med 2000; 108: 627-33.
30. Nishikimi T, Yoshihara F, Morimoto A, et al. Relationship between left ventricular geometry and natriuretic peptide levels in essential hypertension. Hypertension 1996; 28: 22-30.
31. Sakata Y, Yamamoto K, Masuyama T, et al. Ventricular production of natriuretic peptides and ventricular structural remodeling in hypertensive heart failure. J Hypertens 2001; 19: 1905-12.
32. Mukoyama M, Nakao K, Hosoda K, et al. Brain natriuretic peptide as a novel cardiac hormone in humans: evidence for a exquisite dual natriuretic peptide system? J Clin Invest 1991; 87: 1402-12.
33. Kohno M, Minami M, Kano H, et al. Effect of angiotensin-converting enzyme inhibitor on left ventricular parameters and circulating brain natriuretic peptide in elderly hypertensives with left ventricular hypertrophy. Metabolism 2000; 49: 1356-60.